Skip to content

    Hikal

    HIKALGood
    Healthcare·4 Feb 2025
    Management Summary

    Hikal reported a strong Q3 FY25 with revenue of INR448 crores and EBITDA growth of 11% year-on-year, driven by improved product mix and operating leverage. The Pharma business showed significant EBIT growth, while the Crop Protection sector is beginning to stabilize. The company is focusing on NCEs and CDMO opportunities across its segments, with a healthy pipeline and strategic initiatives like Project Pinnacle expected to drive future growth and margin expansion.

    Highlights

    8

    • Q3 FY25 Revenue: INR448 crores.

    • Q3 FY25 EBITDA: INR72 crores, up 11% YoY.

    • 9M FY25 Revenue: INR1,307 crores, up 3% YoY.

    • 9M FY25 EBITDA: INR205 crores, up 18% YoY.

    • Q3 FY25 Pharma Revenue: INR293 crores, with EBIT of INR33 crores (450 bps increase YoY).

    • Q3 FY25 Crop Protection Revenue: INR154 crores, with EBIT of INR14 crores (9% EBIT margin).

    • Operating cash flow (9-month basis): INR102 crores.

    • Interim dividend recommended: INR0.6 per share (30% of face value).

    Key financials

    Metrics

    6

    Periods

    2

    Headline

    3
    • Revenue
      ₹448 Cr
    • EBITDA
      ₹72 Cr
      YoY+11%
    • Gross Debt
      ₹731 Cr

    9M

    3
    • Revenue
      ₹1,307 Cr
      YoY+3%
    • EBITDA
      ₹205 Cr
      YoY+18%
    • Operating Cash Flow
      ₹102 Cr

    Segment breakdown

    • Pharma₹293 Cr65.5%
    • Crop Protection₹154 Cr34.5%
    Donut· Share of Revenue (Q3 FY25)

    Guidance & targets

    18
    CategoryTargetPriority
    Capacity
    Ramp-up from new multipurpose facility at Panoli
    over the next 2 to 3 years
    		Medium
    Profitability
    Full year results
    positive results on a full year basis, led by stronger profit and margin growth
    		Medium
    Profitability
    Animal Health contribution margins
    45% plus
    		High
    Profitability
    Animal Health NCE/CDMO gross margins
    in excess of 50%
    		High
    Profitability
    EBITDA margins
    cross the 20% number
    		High
    Product Launch
    New products from development pipeline
    three to four products annually
    		High
    Commercialization
    CDMO commercial supply
    initiated by the end of calendar year '26, beginning '27
    		High
    Commercialization
    NCE molecules from Phase III trials
    launch towards the end of financial year FY '26, very early '27
    		High
    Revenue
    Food ingredients projects peak revenue
    peak revenue in the next 2 to 3 years
    		Medium
    Revenue
    Animal Health segment business
    in excess of INR400-plus crores
    		High
    Revenue
    NCE CDMO peak potential per molecule
    INR50 crores in the worst case to maybe a few hundred crores per molecule in the best case
    		Medium
    Revenue
    Combined NCE CDMO revenue
    INR400 crores, INR500 crores every year going forward
    		Medium
    Validation
    Animal Health portfolio validation
    complete in the upcoming 2 quarters
    		High
    Revenue Growth
    Company level CAGR
    high teens per year-on-year CAGR
    		High
    Revenue Growth
    Agrochemical business growth drivers
    drive growth FY '27 onwards
    		Medium
    Capex
    Current year capex
    INR140 crores to INR150 crores
    		High
    Capex
    Annual capex
    almost INR150 crores to INR200 crores each year
    		High
    Capex
    Replacement capex percentage
    30% to 40%
    		High

    Risks & concerns

    3
    RiskSeverity

    Intense pricing pressure and dumping from Chinese competitors

    Although China Plus One is expected to strengthen, intense pricing pressure and dumping continues from Chinese competitors for generics and commodity products. — Management acknowledged

    medium

    Short-term pain in crop business

    Management indicated 'a few more quarters of pain left for the crop business' before it returns to a growth phase. — Management acknowledged

    medium

    Volatility and uncertainty regarding US tariffs on Chinese chemicals

    The situation regarding 10% tariffs on chemical companies in China is volatile, and its impact is unknown, potentially being a negotiating tactic. — Management acknowledged

    medium

    Q&A highlights

    3

    “we have currently about, 13 to 14 products in the CDMO under various pipelines, and most of them are between Phase II and Phase III. Phase IV is already getting into launch mode. Out of that, two products are very close to launch, which we expected to be launched in -- towards the end of financial year FY '26. And the others will get launched if everything goes well, in FY '27 and beyond.”

    Provides specific numbers for the CDMO pipeline and clear timelines for commercialization of NCEs, which are key growth drivers.

    asked by Dhaval Shah

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 & 9MFY25 Financial Performance Overview

    Hikal reported a robust Q3 FY25 with revenue reaching INR448 crores and EBITDA growing 11% year-on-year to INR72 crores. For the nine-month period (9MFY25), revenue stood at INR1,307 crores, marking a 3% year-on-year growth, while EBITDA increased by 18% to INR205 crores. The company generated an operating cash flow of INR102 crores on a 9-month basis and recommended an interim dividend of INR0.6 per share.

    02

    Pharmaceutical Business Momentum

    The Pharma business demonstrated strong performance in Q3 FY25, reporting revenues of INR293 crores and an EBIT of INR33 crores, a significant 450 basis points increase year-on-year. This growth was attributed to an improved product mix and operating leverage. The company's CDMO pipeline currently includes 13-14 products, with two NCEs expected to launch towards the end of FY26 or early FY27, and commercial supply for several NCE molecules anticipated by end of calendar year '26.

    03

    Crop Protection Division: Stabilization and Strategy

    The Crop Protection division recorded revenues of INR154 crores in Q3 FY25, with an EBIT of INR14 crores and an EBIT margin of 9%. While the sector faces ongoing pricing pressure from Chinese competitors, management noted signs of stabilization and a rise in domestic demand. Hikal's strategy involves shifting towards new chemical entities (NCEs) and new technologies, with over 8 active projects under filing or launch expected to drive growth from FY27 onwards.

    04

    Animal Health Business: New Growth Vector

    Hikal's Animal Health project, under a long-term agreement with a global innovator, is progressing well, with validation of seven products already completed and the balance expected in the next few months. The company anticipates this segment to become an independent division, projecting over INR400 crores in business over the next 5 years. Contribution margins for this segment are expected to be 45% plus, with NCE/CDMO type products potentially exceeding 50% gross margins.

    05

    CDMO Pipeline and Future Commercialization

    The CDMO business is a key focus, with several projects advancing towards validation and commercialization. Beyond the two NCEs nearing launch by FY26/early FY27, the company aims to launch 3-4 new products annually from its 8-9 product development pipeline. Management estimates that a combination of multiple NCE CDMO product launches could generate INR400-500 crores in revenue annually going forward⏳, with individual molecules potentially contributing INR50 to a few hundred crores at peak.

    06

    Strategic Initiatives and Capital Allocation

    Hikal's 'Project Pinnacle' strategy, launched two years ago, is focused on identifying future opportunities, improving operational efficiency, and strengthening its market position. The company is committed to R&D, investing 4.5% to 5% of its revenue, and aims for a high-teens year-on-year CAGR over the next 3-5 years, with EBITDA margins targeted to cross 20%. Capex for FY25 is guided at INR140-150 crores, with annual capex of INR150-200 crores planned for subsequent years, 30-40% of which will be for replacement and the rest for debottlenecking and growth.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.